About Roche
Roche is a publicly listed company based in Basel (Switzerland) founded in 1896. Pharmaceuticals and diagnostics kits are developed for various diseases. It operates on a HealthTech and Professional Services model. The company has 103,250 employees. Roche has completed 50 acquisitions, including 454 Life Sciences, Adheron Therapeutics and Anadys Pharma. Its chief executive, as recorded, is Thomas Schinecker. Its website roche.com draws about 1.3 million monthly visits. Roche offers products and services including Pharma Solutions, Diagnostic Solutions, and Susvimo. Its focus areas include Pharmaceuticals, Drug Development, Medical Devices and Diagnostics. Its legal entity is F. Hoffmann-La Roche Ltd.
Company details
Roche is engaged in the development of innovative medicines and diagnostic solutions to improve health outcomes. The company operates in the healthcare sector, addressing urgent challenges through pharmaceuticals and diagnostics. Solutions are provided to prevent, stop, and cure diseases by identifying high-risk patients, accurately diagnosing conditions, and delivering targeted treatments. Efforts are directed toward revolutionizing patient care with technologies like Brainshuttle for CNS disease treatment.
- Annual Revenue$77.61 B (USD)1.69as on Dec 31, 2025
- Net Profit$16.25 B (USD)55.61as on Dec 31, 2025
- EBITDA$28.59 B (USD)4.59as on Dec 31, 2025
- InvestorsSoftBank Group
& 4 more
- Employee Count103,250
- Investments & Acquisitions454 Life Sciences
& 49 more
Associated legal entities of Roche
Roche is associated with 2 registered companies on The Company Check. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Roche Products (India) Private Limited CIN U74999MH1994PTC077533 | Active | 05 Apr 1994 | Mumbai, Maharashtra | ₹1,296 Cr | 397 | 6 | View details |
| Roche Diagnostics India Private Limited CIN U85195MH1988PTC141417 | Active | 07 Jun 1988 | Mumbai, Maharashtra | ₹1,869 Cr | 442 | 4 | View details |
Products & Services of Roche
Roche offers a comprehensive portfolio of products and services, including Pharma Solutions, Diagnostic Solutions, and Susvimo.
Innovative medicines are developed to treat various diseases.
Advanced diagnostic tools are provided for accurate disease detection.
Continuous delivery treatment is offered for diabetic macular edema.
Apps and channels of Roche
its YouTube channel Genentech has 77K subscribers and 30 videos.
Videos from Roche
The most watched videos on Roche's YouTube channel, Genentech (77K subscribers). Click a video to play it here.
More on Genentech.
Funding Insights of Roche
- Total Rounds 18
- First Round $459,937
(May 2004)
- Investors Count 5
Latest 10 of 18 funding rounds of Roche with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | Post-IPO | – | – | ||
| Jun 2022 | Grant | – | – | ||
| Aug 2021 | Post-IPO | – | – | ||
| Mar 2021 | $23.93M | Grant | – | – | |
| Mar 2021 | $338,722 | Grant | – | – | |
| Jan 2021 | $574,917 | Grant | – | – | |
| Jan 2020 | Grant | – | – | ||
| Nov 2019 | $805,489 | Grant | – | – | |
| Jan 2019 | $805,489 | Grant | – | – | |
| Dec 2017 | $803,702 | Grant | – | – |
5 investors in total: 5 institutional.
Investors in Roche
Roche has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include SoftBank Group, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provides financial advisory, investment planning, retirement services, and trust management for clients. | nhtrust.com | |||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Investments are directed toward multiple sectors via fund of funds. | 1981 | group.softbank | Minato City, Japan | |
Business and energy news is delivered via an online platform. | 1954 | bafa.de | Eschborn, Germany | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Roche
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Roche
The boards of the 2 registered companies of Roche currently have 7 directors; the longest-serving is Brajesh Rameshwardas Daga, appointed in 2016. 47 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Brajesh Rameshwardas Daga DIN 02349092 | Director | 01 Apr 2016 | 10 yrs 7 mo | Roche Diagnostics India Private Limited |
| Rishubh Gupta DIN 09414318 | Managing Director | 25 Sep 2023 | 3 yrs 1 mo | Roche Diagnostics India Private Limited, Roche Products (India) Private Limited |
| Soley Guzel DIN 10802847 | Additional Director | 12 Nov 2024 | 1 yr 11 mo | Roche Diagnostics India Private Limited |
| Nicolas Dominik Mirko Gut DIN 10881130 | Director | 06 Jan 2025 | 1 yr 9 mo | Roche Products (India) Private Limited |
| Nilesh Avinash Limaye DIN 07855620 | Additional Director | 01 Apr 2025 | 1 yr 7 mo | Roche Products (India) Private Limited |
| Rajwinder Mehdwan DIN 11002158 | Managing Director | 01 Apr 2025 | 1 yr 7 mo | Roche Products (India) Private Limited |
| Francois Du Toit DIN 10990187 | Additional Director | 01 Apr 2025 | 1 yr 7 mo | Roche Products (India) Private Limited |
People of Roche
442 people are tracked at Roche (182 in leadership, 10 in board & advisors, 250 in team); the tracked headcount is 103,250.
| Name | Role | Group |
|---|---|---|
Thomas Schinecker | CEO | Leadership |
Yasmin Köller | Head Of Integrated Marketing | Leadership |
Dheeraj Manchanda | Head - Operations & Channel Management | Leadership |
Joab C. | Director, Global Diagnostics Partnering | Leadership |
Lubomira Osten | Finance Business Partner - Diabetes Care R&d | Leadership |
Matthias Ochs | Head Managed Service Center | Leadership |
Nims Dhawan | Global OD Consulting Partner | Leadership |
Mallorie Poiseau | Executive Recruiting Partner EMEA / APAC | Leadership |
Yunus Rasmi | Head Of Operation Single Use Technology | Leadership |
Elie Fux | Group Head Mass Spectrometry Applications | Leadership |
Hafsa Shamsie | Managing Director | Leadership |
Roel Panneels | Head Of Business Operations | Leadership |
Veena Gonsalves | Head Channel Partner Management | Leadership |
Nitin Wadhwa | Director Sales | Leadership |
Xuemin Liu | Director, Companion Diagnostics, Roche Diagnostics | Leadership |
Christoph Rutz | Chapter Lead R&d | Department Head, R&d Corelab | Leadership |
Heather Yoder | Director, People & Culture | Leadership |
Taksina Ratanasakdi | Chief Transformation Officer (agile Transformation) & Enterprise Finance | Leadership |
Matheus B Vieira | President & General Manager - Roche Diagnostics Canada | Leadership |
Rahul Kamath | Chief Operating Officer | Leadership |
422 more people are available in the full profile.
Complete people profiles for Roche
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Roche
Roche is a publicly listed company on the SIX with ticker symbol RO in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Dec 2002
- Listed onOTCMKTS: RHHBY
- Listed entityRoche Holding Ltd
- Exchange sectorHealth technology
- ISINCH0012032113
- Share price323.60 CHF (+0.19% on the day) · 2026-05-11
- Market capitalisation251,679,753,451.00 CHF
- Price to earnings20.2
- EPS (diluted, trailing year)16.04 CHF
- Dividend yield3.34%
- Volume (last session)3,853
- Analyst consensusBuy
Financials of Roche
Figures of Roche Diagnostics India Private Limited, the primary company behind Roche, for FY 2025. Revenue was ₹1,869 Cr (+16% year on year). Net profit was ₹43.76 Cr (2% margin). EBITDA was ₹316 Cr (17% margin). Revenue has grown at a compounded annual rate of +6% over three years and +12% over five years.
- ₹1,869 CrRevenue · FY 2025 · +16% YoY
- ₹43.76 CrNet profit · 2% margin
- ₹316 CrEBITDA · 17% margin
- ₹14.92 CrPaid-up capital
- 442Employees (provident fund records)
- +6%Revenue CAGR, 3 years
- +12%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 61.52B CHF | 12.88B CHF | 22.66B CHF |
| 2024 | 60.49B CHF | 8.28B CHF | 21.66B CHF |
| 2023 | 58.72B CHF | 11.50B CHF | 19.82B CHF |
| 2022 | 63.28B CHF | 12.42B CHF | 22.00B CHF |
| 2021 | 62.80B CHF | 13.93B CHF | 21.73B CHF |
Balance sheet, profit and loss, cash flow and ratios of Roche Diagnostics India Private Limited are on its company page.
Detailed financial statements for Roche
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Roche
Roche has strategically engaged in corporate development activities, having acquired 50 companies. Notable acquisitions include 454 Life Sciences, Adheron Therapeutics and Anadys Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | poseida.com | San Diego, United States | 2015 | Nov 2024 | $1.5B | |
Provider of therapeutics related to oncology, autoimmune and metabolic disease | regor.com | Boston, United States | 2018 | Sep 2024 | $850M | |
Cloud based diagnostics platform for point of care diagnosing | lumiradx.com | Waltham, United States | 2014 | Jan 2024 | $350M | |
Disease-modifying therapies for metabolic diseases are developed. | carmot.us | Berkeley, United States | 2008 | Dec 2023 | $2.7B | |
Therapeutics for inflammatory and fibrotic diseases are developed. | telavanttx.com | New York, United States | 2022 | Oct 2023 | $7.1B | |
Protein-based drugs for cancer treatment are developed. | goodtherapeutics.com | Seattle, United States | 2016 | Sep 2022 | $250M | |
Kits and reagents for research and diagnostics are supplied. | tib-molbiol.de | Berlin, Germany | 1990 | Sep 2021 | •••• | |
Instruments and test panels for multiplexed molecular diagnostics are provided. | genmarkdx.com | San Diego, United States | 1993 | Mar 2021 | $1.8B | |
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis | enterprisetherapeutics.com | Brighton, United Kingdom | 2014 | Oct 2020 | $97.14M | |
Inhibitors of the inflammasome are developed for chronic inflammatory diseases. | inflazome.com | Dublin, Ireland | 2016 | Sep 2020 | $451M |
Complete acquisition details for Roche
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Roche
14 dated milestones of Roche across 128 years, from founding to its latest funding, stage changes and deals.
- Founded Roche is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $460K.
- Acquisition Acquires Inflazome.
- Acquisition Acquires Enterprise Therapeutics.
- Acquisition Acquires GenMark Diagnostics.
- Acquisition Acquires TIB Molbiol.
- Acquisition Acquires Bonum Therapeutics.
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires Telavant.
- Acquisition Acquires Carmot.
- Acquisition Acquires LumiraDx.
- Acquisition Acquires Regor.
- Acquisition Acquires Poseida Therapeutics.
Web traffic of Roche
The website of Roche (roche.com) receives about 1.3M visits a month and ranks #42,219 among all websites worldwide, #1,067 in Biotechnology and Pharmaceuticals.
- Monthly visits1.3M
▲ 14.6% vs previous month
- Unique visitors527K
per month
- Global rank#42,219
among all websites
- Category rank#1,067
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit3.7
- Average visit2 min 42 sec
- DevicesDesktop 57% · Mobile 43%
Websites whose visitors overlap most with Roche. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novartis.com | 100% | 948.8K | #58,822 | View details | |
| pfizer.com | 93% | 1.9M | #24,984 | View details | |
rocheusa.com | rocheusa.com | 84% | – | ||
| astrazeneca.com | 81% | 1.3M | #48,983 | View details | |
| merck.com | 81% | 656.8K | #78,842 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Roche
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Roche
Complete news archive for Roche
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Roche
Roche was founded in 1896 and raised its 1st funding round 108 years after it was founded.
Roche is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Thomas Schinecker is the CEO of Roche, as recorded in our data.
Roche has 103,250 employees.
Annual revenue of Roche is $77.61B as on Dec 31, 2025.
Roche is engaged in the development of innovative medicines and diagnostic solutions to improve health outcomes. The company operates in the healthcare sector, addressing urgent challenges through pharmaceuticals and diagnostics. Solutions are provided to prevent, stop, and cure diseases by identifying high-risk patients, accurately diagnosing conditions, and delivering targeted treatments. Efforts are directed toward revolutionizing patient care with technologies like Brainshuttle for CNS disease treatment.
Roche offers Pharma Solutions, Diagnostic Solutions, and Susvimo.
Yes, Roche is publicly traded on SIX under the ticker symbol RO.
Roche has made 50 acquisitions, including 454 Life Sciences, Adheron Therapeutics, and Anadys Pharma.
Roche has 5 investors. Key investors include SoftBank Group, HHS, European Union, BAFA, and NHTrust.
Roche is associated with 2 legal entities: Roche Diagnostics India Private Limited, Roche Products (India) Private Limited.
The legal entities of Roche currently have 8 directors, including Rishubh Gupta, Brajesh Rameshwardas Daga, Soley Guzel and others.